20 July 2017 - Teva Pharmaceutical Industries today announced that the NICE in England has recommended Cinqaero (reslizumab) in its final appraisal determination. 

Cinqaero is a humanised interleukin-5 (IL-5) antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Following issuance of the final appraisal determination, NICE will provide its formal guidance to the NHS in England. The full NICE recommendations can be viewed on their website.

Read Teva Pharmaceuticals press release